Position in SVTR
Snapshot 2026-11-05- Startup SignalsTop 25%↓28
- Life SciencesTop 25%↓2
- AI for ScienceTop 50%↓1
- Drug DiscoveryTop 50%–
About
Nutshell Therapeutics (Shanghai Yudao Biotechnology), founded in 2013 in Shanghai, develops allosteric small-molecule drugs for hard-to-drug targets using its AlloMatrix allosteric database and AlloStar AI+physics platform; its p53 Y220C reactivator NTS071 is in a global Phase I trial.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Investor· 4
Funding history
- 2026-09-15Series C1数千万美元
Investors · Trustar Capital, Decheng Capital, Fortune Capital, 中生锡创鼎祺基金Source · chinaventure.com.cn ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Nutshell Therapeutics
AI and physics-based computation for allosteric small-molecule drug discovery against hard-to-drug targets such as transcription factors
Series C · 2026-09
—
United States
BusinessLatest roundTotal raisedDate- Neomera BioLab
AI-driven peptide/biologics drug discovery platform targeting hard-to-drug membrane protein targets such as GPCRs and ion channels…
— - Kekulai
Automates end-to-end small-molecule drug discovery with AI agent platform Allchymie…
— - Odyssey Therapeutics
Small-molecule and protein therapeutics developed with AI and machine learning
Series C · $101M · 2023-12
$101M
China
BusinessLatest roundTotal raisedDate- NeuShen Therapeutics
Novel drugs for CNS psychiatric and neurological disorders…
Series B · 2026-09
— - Phil Rivers Technology
Computational medicine and life world models using AI and high-performance computing to simulate disease mechanisms and drug efficacy…
Series A2 · 2026-08
— - Drug Farm
Drug developer using genetics and AI to discover first-in-class targets
Series D+ · $55M · 2026-07
$55M
Europe
BusinessLatest roundTotal raisedDate- Allox
AI and high-throughput genetics to map protein allostery, developing small-molecule drugs for hard-to-drug targets
Seed · 2026-10
— - Relation Therapeutics
Multi-omics plus active graph machine learning to discover and validate novel drug targets, partnered with GSK (fibrosis and osteoarthritis)
Undisclosed · $61M · 2025-12
$61M - Isomorphic Labs
AI-driven drug design platform (IsoDDE engine): uses AlphaFold-based technology to predict protein structures and design new drug molecules; builds it…
Series B · $2.7B · 2026-05
$2.7B
Other / unspecified
BusinessLatest roundTotal raisedDate- 深度细胞
Combines AI with multiscale molecular physics to build a "virtual cell world model" for disease mechanism discovery and drug design
Seed · $14M · 2026-08
$14M - Galux
AI plus physics-based protein/antibody design platform (GaluxDesign) for drug discovery
Series B · $58M · 2026-02
$58M - Congruence
Computation-driven drugs for genetic diseases (including CGX-926)
Undisclosed · $32M · 2025-09
$32M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Related coverage
Investors that may fit
Dimension Capital
10 Life Sciences deals in the last 24 months · 5 at a nearby stage · 1 in East China
Request intro →OrbiMed Advisors
9 Life Sciences deals in the last 24 months · 2 at a nearby stage · 4 in East China
Request intro →Qiming Venture Partners
9 Life Sciences deals in the last 24 months · 4 at a nearby stage · 7 in East China
Request intro →Lilly Asia Ventures
8 Life Sciences deals in the last 24 months · 4 at a nearby stage · 7 in East China
Request intro →Matrix Partners China
6 Life Sciences deals in the last 24 months · 2 at a nearby stage · 4 in East China
Request intro →B Capital
5 Life Sciences deals in the last 24 months · 4 at a nearby stage · 1 in East China
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.